EUVIMEDEUVIMED entdecken
Open Access

RNA interference therapy in acute hepatic porphyrias

Makiko Yasuda iD, Siobán Keel iD, Manisha Balwani iD

Blood · 2023

DOI: 10.1182/blood.2022018662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Makiko Yasuda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Porphyrias, Porphyrias, Hepatic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The acute hepatic porphyrias (AHPs) are inherited disorders of heme biosynthesis characterized by life-threatening acute neurovisceral attacks precipitated by factors that upregulate hepatic 5-aminolevulinic acid synthase 1 (ALAS1) activity. Induction of hepatic ALAS1 leads to the accumulation of porphyrin precursors, in particular 5-aminolevulinic acid (ALA), which is thought to be the neurotoxic mediator leading to acute attack symptoms such as severe abdominal pain and autonomic dysfunction. Patients may also develop debilitating chronic symptoms and long-term medical complications, including kidney disease and an increased risk of hepatocellular carcinoma. Exogenous heme is the historical treatment for attacks and exerts its therapeutic effect by inhibiting hepatic ALAS1 activity. The pathophysiology of acute attacks provided the rationale to develop an RNA interference therapeutic that suppresses hepatic ALAS1 expression. Givosiran is a subcutaneously administered N-acetylgalactosamine–conjugated small interfering RNA against ALAS1 that is taken up nearly exclusively by hepatocytes via the asialoglycoprotein receptor. Clinical trials established that the continuous suppression of hepatic ALAS1 mRNA via monthly givosiran administration effectively reduced urinary ALA and porphobilinogen levels and acute attack rates and improved quality of life. Common side effects include injection site reactions and increases in liver enzymes and creatinine. Givosiran was approved by the US Food and Drug Administration and European Medicines Agency in 2019 and 2020, respectively, for the treatment of patients with AHP. Although givosiran has the potential to decrease the risk of chronic complications, long-term data on the safety and effects of sustained ALAS1 suppression in patients with AHP are lacking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PorphyriasPorphyrias, HepaticHemePainAminolevulinic AcidHumansRNA InterferenceQuality of LifePorphobilinogen Synthase

Substanzen

HemeAminolevulinic AcidPorphobilinogen Synthase

Autor:innen und Institutionen

  • Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Department of Medicine, Division of Hematology, University of Washington, Seattle, WA.

ORCID-Profile: Makiko Yasuda, Siobán Keel, Manisha Balwani

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Yasuda, M., Keel, S., & Balwani, M. (2023). RNA interference therapy in acute hepatic porphyrias. Blood. https://doi.org/10.1182/blood.2022018662

Vancouver

Yasuda M, Keel S, Balwani M. RNA interference therapy in acute hepatic porphyrias. Blood. 2023. doi:10.1182/blood.2022018662

BibTeX
@article{Yasuda2023,
  author = {Yasuda, Makiko and Keel, Siobán and Balwani, Manisha},
  title = {RNA interference therapy in acute hepatic porphyrias},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018662}
}
Kostenlos starten →